
News|Articles|April 1, 2010
Formulary Digital Edition April 2010
Reducing cardiovascular risk is patients with type 2 diabetes: management of dyslipidemia; Focus on naproxicond; Drug Watch: Agents in late-stage development for the treatment of hepatitis C
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
Atopic dermatitis care advances in 2025 with new biologics, topicals and oral therapies
3
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
4
UC Davis develops new drug for bladder cancer patients
5


















































